Hospital
Lakeland Community Hospital Watervliet
Lakeland Community Hospital Watervliet was paid $9.85M by Medicaid between Jan 2018 and Dec 2024, across 167 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoLAKELAND COMMUNITY HOSPITAL WATERVLIET
WATERVLIET, MI 49098
WATERVLIET, MI 49098
33aNPI1700994845assigned 08/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.85M
24GClaims327,310
24DCodes billed167
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#64 of 86
Median peer was paid$21.55M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COX, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,878 | $985K | |
| 2019 | 39,321 | $994K | |
| 2020 | 38,125 | $1.03M | |
| 2021 | 52,926 | $1.67M | |
| 2022 | 58,262 | $1.86M | |
| 2023 | 59,352 | $1.86M | |
| 2024incomplete | 39,446 | $1.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 17,011 | 15,913 | $2.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 9,866 | 9,167 | $1.95M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 4,328 | 4,163 | $1.25M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.7% | 6,288 | 5,510 | $655K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 2,019 | 1,988 | $355K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.5% | 13,426 | 4,165 | $340K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 2,702 | 1,788 | $294K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 3,003 | 2,959 | $218K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 4,807 | 3,668 | $191K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.8% | 2,195 | 2,166 | $180K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 4,856 | 4,195 | $163K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 2,817 | 2,762 | $145K |
155 more codes
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.4% | 5,035 | $141K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 3,351 | $137K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.3% | 2,980 | $125K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 6,498 | $110K |
| 73630 | <1% | 2,531 | $70K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 581 | $69K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,595 | $68K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,411 | $68K |
| 80053 | Comprehensive metabolic panel | <1% | 21,429 | $64K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,952 | $64K |
| 73564 | <1% | 1,592 | $63K | |
| 80061 | Lipid panel | <1% | 8,133 | $62K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 505 | $54K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,270 | $52K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,258 | $46K |
| 27687 | <1% | 76 | $41K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 370 | $39K |
| 73610 | <1% | 1,472 | $39K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,877 | $38K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,604 | $37K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,607 | $37K |
| 97162 | <1% | 657 | $34K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 388 | $32K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 650 | $32K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,993 | $31K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,926 | $30K |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,230 | $24K |
| 73030 | <1% | 928 | $22K | |
| 73110 | <1% | 787 | $22K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 642 | $18K |
| 73130 | <1% | 794 | $17K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,251 | $16K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,724 | $13K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 174 | $11K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 87 | $11K |
| 83655 | <1% | 1,595 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 742 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,860 | $10K |
| 84439 | <1% | 2,338 | $10K | |
| 85027 | <1% | 2,986 | $10K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 327 | $10K |
| 87088 | <1% | 3,472 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,032 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,104 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,929 | $7K |
| 82728 | <1% | 888 | $6K | |
| 87808 | <1% | 1,440 | $6K | |
| 73140 | <1% | 214 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,230 | $5K |
| 64450 | <1% | 158 | $5K | |
| 87905 | <1% | 1,515 | $5K | |
| 64447 | <1% | 169 | $5K | |
| 82043 | <1% | 1,736 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 25 | $5K |
| 87186 | <1% | 1,473 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 81 | $4K |
| 82607 | <1% | 594 | $4K | |
| 97163 | <1% | 78 | $4K | |
| 84153 | <1% | 412 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 284 | $3K |
| 83735 | <1% | 3,148 | $3K | |
| 87077 | <1% | 1,055 | $3K | |
| 93975 | <1% | 27 | $3K | |
| 84702 | <1% | 2,103 | $3K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 24 | $3K |
| 85610 | <1% | 2,085 | $3K | |
| 83550 | <1% | 606 | $3K | |
| 86140 | <1% | 1,271 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 43 | $3K |
| 83540 | <1% | 760 | $2K | |
| 72110 | <1% | 67 | $2K | |
| 86803 | <1% | 303 | $2K | |
| 73502 | <1% | 91 | $2K | |
| 86480 | <1% | 63 | $2K | |
| 85652 | <1% | 1,434 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,339 | $2K |
| 80306 | <1% | 425 | $2K | |
| 81001 | <1% | 8,895 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 27 | $1K |
| 83690 | <1% | 4,734 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 95 | $1K |
| 87390 | <1% | 86 | $969.38 | |
| 87631 | <1% | 32 | $937.18 | |
| 73080 | <1% | 44 | $858.78 | |
| 76801 | <1% | 13 | $781.28 | |
| 86702 | <1% | 86 | $671.28 | |
| 71271 | <1% | 12 | $662.00 | |
| 80076 | <1% | 145 | $628.22 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,834 | $583.46 |
| 82746 | <1% | 80 | $523.40 | |
| 86038 | <1% | 79 | $517.60 | |
| 87081 | <1% | 222 | $515.40 | |
| 83880 | <1% | 142 | $493.54 | |
| 86376 | <1% | 73 | $485.78 | |
| 87206 | <1% | 159 | $475.55 | |
| 85730 | <1% | 567 | $471.50 | |
| 86701 | <1% | 86 | $440.88 | |
| 86780 | <1% | 49 | $381.54 | |
| 81025 | <1% | 4,190 | $330.96 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 22 | $300.95 |
| 80050 | General health panel | <1% | 12 | $289.00 |
| 82947 | <1% | 93 | $237.71 | |
| 86665 | <1% | 12 | $204.40 | |
| 82570 | <1% | 72 | $175.46 | |
| 87102 | <1% | 37 | $173.85 | |
| 83605 | <1% | 1,296 | $151.46 | |
| 84207 | <1% | 12 | $147.42 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 12 | $129.24 |
| 84484 | <1% | 2,719 | $123.62 | |
| 82247 | <1% | 37 | $105.30 | |
| 84481 | <1% | 13 | $99.10 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,549 | $89.04 |
| 86664 | <1% | 12 | $86.10 | |
| 85379 | <1% | 436 | $78.28 | |
| 87040 | <1% | 359 | $67.50 | |
| 86308 | <1% | 13 | $21.21 | |
| 96376 | <1% | 933 | $18.59 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 953 | $11.54 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,513 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 814 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 1,416 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,833 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 7,442 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 647 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 916 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 465 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 41 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 167 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 601 | $0.00 |
| A9270 | Non-covered item or service | 0% | 351 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 328 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 524 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 211 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 506 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,092 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 51 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 47 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 103 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 56 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 36 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 1,650 | $0.00 |
| 90715 | 0% | 54 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,996 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 79 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 228 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 60 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 148 | $0.00 |
| 94664 | 0% | 433 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 969 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 26 | $0.00 |
| 76942 | 0% | 366 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 470 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 183 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOX, MATTHEW (CFO)
Parent organizationCOREWELL HEALTH
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.